

TESTING THE HUMAN PAPILLOMAVIRUS IN THE PRIMARY SCREENING OF THE CERVICAL DISEASE

Doniyorbek Shuxratbekovich Khasanov*; Dilfuzahon Zakirzhanovna Mamarasulova**

* PhD, Docent,

Department of Oncology and Medical Radiology,
Andijan State Medical Institute, Andijan, UZBEKISTAN

**Associate Professor,

Doctor of Medical Sciences,
Department of Oncology and Medical Radiology,
Andijan State Medical Institute, Andijan, UZBEKISTAN

Email id: dilya2580559@gmail.com

DOI: **10.5958/2249-7137.2021.02740.3**

ABSTRACT

This article discusses the issues of HPV testing by cytological screening. The combination of cytology and HPV testing is considered the mainstay of screening. These methods complement each other since cytological examination has high specificity, but low sensitivity, while HPV testing, on the contrary, is characterized by low specificity and high sensitivity.

KEYWORDS: *Cervical Cancer, Screening, Cytology.*

REFERENCES

1. Abdumutalibova SK, Mamarasulova DZ, Ishanchaeva NQ, Nabijonova GK. Etiology and diagnosis of benign breast diseases and their relationship with diseases of the reproductive system in fertilized women. *ACADEMICIA: An International Multidisciplinary Research Journal*. 2021;11(9):947-952.
 2. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. *Vaccine*. 2012;30:88–99.
 3. Bains I, Choi YH, Soldan K, Jit M. Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England. *Int. J. Gynecol. Cancer* 2019; ijgc-2018-000161
 4. Carestiato FN, Afonso LA, Moyses N, Almeida Filho GL, Velarde LG, Cavalcanti SM. An upward trend in DNA p16ink4a methylation pattern and high risk HPV infection according to the severity of the cervical lesion. *Rev Inst Med Trop Sao Paulo*. 2013;55(5):329–334.
 5. Mamarasulova D, Abduhakimov A, Tursunov D, Urmanbaeva D, Jalolov O, Isaev Z. Comparative Analysis of the Mortality Structure among the Population of Andijan Region for 2016–2018. *J. Cardiovasc Disease Res.*, 2020;11(2):01–03.
 6. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in
-

- women 30 years and older. *Int. J. Cancer.* 2009;124:516–520.
7. O'Connor M, O'Leary E, Waller J, Gallagher P, Martin CM, O'Leary JJ, et al. Socio-economic variations in anticipated adverse reactions to testing HPV positive: implications for the introduction of primary HPV-based cervical screening. *Preventive Med.* 2018;115:90–96.
 8. Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. *Expert Rev. Anti Infect. Ther.* 2010;8:1139–1162.
 9. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. *Lancet.* 2014;383:524–532.
 10. Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. *BMJ.* 2019;364:l240.
 11. ASCUS-LSIL Triage Study (ALTS). Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. *American journal of obstetrics and gynecology.* 2003;188:1383–92.
 12. Schwarz TF, Galaj A, Spaczynski M, Wysocki J, Kaufmann AM, Poncelet S, et al. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15–55 years of age. *Cancer Med.* 2017;6:2723–2731
 13. Torres KL, Marino JM, Pires Rocha DA, de Mello MB, de Melo Farah HH, Reis R, D. S, et al. Self-sampling coupled to the detection of HPV 16 and 18 E6 protein: A promising option for detection of cervical malignancies in remote areas. *PLoS ONE.* 2018;13:e0201262.
 14. Tsuda H, Hashiguchi Y, Nishimura S, Kawamura N, Inoue T, Yamamoto K. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. *Gynecol Oncol.* 2003;91(3):476–485.
 15. Wright TC, Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. *Journal of lower genital tract disease.* 2007;11:201–22
 16. Yakubbekova SS, Israilov RI, Mamarasulova DZ, Azizov YD., Inaqova ZT. Clinical And Morphological Features And Histological Variants Of Borderline Types Of Ovarian Tumors. *The American Journal of Medical Sciences and Pharmaceutical Research,* 2021;3(01):152-158.
 17. Yang H, Hu H, Gou Y, Hu Y, Li H, et al. Combined detection of Twist1, Snail1 and squamous cell carcinoma antigen for the prognostic evaluation of invasion and metastasis in cervical squamous cell carcinoma. *Int J Clin Oncol.* 2018; 23(2):321-328.
 18. ZurHausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. *J Natl Cancer Inst.* 2000;92(9):690–698.